Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis

Summary

This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.

Conditions

• Peritoneal Dialysis-associated Peritonitis
• Vitamin D Deficiency

Interventions

DRUG

Cholecalciferol

Patients in the intervention group will receive oral cholecalciferol 4000U per day.

DRUG

Placebo

Patients in the control group will receive placebo 2 capsules per day.

Sponsors & Collaborators

• Peking University Third Hospital

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Beijing Haidian Hospital

  collaborator OTHER

• Peking University Shenzhen Hospital

  collaborator OTHER

• Miyun District of Peking University First Hospital

  collaborator UNKNOWN

• Beijing Fangshan District Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Peking University International Hospital

  collaborator OTHER

• Beijing Tsinghua Changgeng Hospital

  collaborator OTHER

• Beijing Anzhen Hospital

  collaborator OTHER

• Capital Medical University

  collaborator OTHER

• Peking University First Hospital

  lead OTHER

Principal Investigators

• Jie Dong · Peking University First Hospital

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

19 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-06-15

Primary Completion

2026-03-31

Completion

2026-05-31

Countries

• China

Study Locations